Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, recently provided an update on its lead drug candidate Lucid-MS and its commercial product unbuzzd during an appearance on the BioMedWire Podcast. Executive Co-Chairman and Co-Founder Anthony Durkacz detailed the company's strategy for advancing Lucid-MS into human clinical trials and highlighted the commercial potential of unbuzzd, a product designed to accelerate alcohol metabolism.
Lucid-MS is a patented new chemical entity that has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying cause of multiple sclerosis (MS). The company has filed an investigational new drug application for a Phase 2 clinical trial, which could mark the first administration of Lucid-MS to human MS patients. This development is significant as it aims to address mobility damage associated with MS, a condition that affects millions worldwide and currently has limited treatment options for progressive forms of the disease.
In addition to its clinical pipeline, Quantum BioPharma has commercialized unbuzzd, an over-the-counter product that accelerates alcohol metabolism. The company spun out the product to Unbuzzd Wellness Inc. (UWI), retaining a 19.84% ownership stake as of March 31, 2026, and a royalty agreement. Under the terms, Quantum BioPharma receives 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products for pharmaceutical and medical uses. This dual strategy allows Quantum BioPharma to generate near-term revenue from unbuzzd while funding the development of Lucid-MS and other pipeline candidates.
Durkacz emphasized that the combination of clinical-stage development and commercial revenue is a deliberate approach to de-risk the business and provide multiple pathways for growth. The company is targeting not only MS but also other neurodegenerative and metabolic disorders, as well as alcohol misuse conditions. The unbuzzd product is already available through unbuzzd.com, and the company continues to explore additional applications.
The announcement comes as Quantum BioPharma prepares for its Phase 2 trial, which will be a key milestone for the company. If successful, Lucid-MS could offer a novel treatment for MS patients, potentially slowing or reversing disease progression. The broader implications for the industry include the validation of new chemical entities targeting myelin repair, an area of high unmet medical need. For investors, the progress of Lucid-MS and the commercial traction of unbuzzd could drive significant value, as reflected in the company's growing visibility in the biotech sector.
Quantum BioPharma is publicly traded on NASDAQ under the symbol QNTM and on the CSE under QNTM. More information about the company and its developments is available in its newsroom.
